Marker Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, reporting a net loss of $1,844,472 for the third quarter.
Key Highlights
- Net loss of $1,844,472 for the three months ended September 30, 2026, compared to a net loss of $1,998,662 in the same period of 2025, according to the filing.
- Nine-month net loss of $6,849,979 for the period ended September 30, 2026, down from $10,460,410 for the nine months ended September 30, 2025.
- Cash and cash equivalents of $9,039,785 as of September 30, 2026, compared to $16,068,048 at December 31, 2025.
- Total assets of $12,499,291 as of September 30, 2026, versus $19,070,997 at December 31, 2025.
- Grant income of $1,292,996 partially offset operating losses in Q3 2026, the filing disclosed.
- 16,673,127 shares of common stock outstanding as of November 13, 2026, with no change in share count during the nine months ended September 30, 2026.
Marker Therapeutics Reports Reduced Operating Losses in Third Quarter 2026
According to the quarterly report filed on NASDAQ:MRKR, Marker Therapeutics reported total operating expenses of $3,229,253 for the three months ended September 30, 2026, compared to $3,369,664 in the same quarter of 2025. Research and development expenses declined to $2,172,263 from $2,345,843 year-over-year, while general and administrative expenses increased modestly to $1,056,990 from $1,023,821 over the same period, the filing stated.
For the nine months ended September 30, 2026, the company reported total operating expenses of $9,922,153, a decrease from $13,449,657 for the comparable period in 2025. The filing noted that the prior-year nine-month period included a $453,135 loss on early termination of a vendor agreement that did not recur in 2026. Research and development costs for the nine-month period fell to $6,491,151 from $9,658,322. Grant income for the nine months ended September 30, 2026 was $2,726,266, up from $2,443,225 in the prior-year period, according to the filing.
The company's balance sheet as of September 30, 2026 reflected total stockholders' equity of $10,502,879, down from $16,796,814 at December 31, 2025, the filing disclosed. The accumulated deficit stood at $466,030,777 as of September 30, 2026, compared to $459,180,798 at December 31, 2025. Stock-based compensation of $556,044 was recorded for the nine months ended September 30, 2026. The company reported a net loss per share of $0.10 (basic and diluted) for Q3 2026, versus $0.12 in Q3 2025, based on a weighted average share count of 19,314,742.
What Was Disclosed
Marker Therapeutics filed its unaudited condensed consolidated financial statements for the quarter and nine months ended September 30, 2026, showing reduced net losses year-over-year, lower cash balances, and an accumulated deficit of $466,030,777 as of the filing period.





Please wait processing your request...